Tilki, Derya, Willemse, Peter-Paul M.; Davis, Niall F.; Grivas, Nikolaos; Zattoni, Fabio; Lardas, Michael; Briers, Erik; Cumberbatch, Marcus G.; De Santis, Maria; Dell'Oglio, Paolo; Donaldson, James F.; Fossati, Nicola; Gandaglia, Giorgio; Gillessen, Silke; Grummet, Jeremy P.; Henry, Ann M.; Liew, Matthew; MacLennan, Steven; Mason, Malcolm D.; Moris, Lisa; Plass, Karin; O'Hanlon, Shane; Omar, Muhammad Imran; Oprea-Lager, Daniela E.; Pang, Karl H.; Paterson, Catherine C.; Ploussard, Guillaume; Rouvière, Olivier; Schoots, Ivo G.; van den Bergh, Roderick C.N.; Van den Broeck, Thomas; van der Kwast, Theodorus H.; van der Poel, Henk G.; Wiegel, Thomas; Yuan, Cathy Yuhong; Cornford, Philip; Mottet, Nicolas; Lam, Thomas B.L., Koç University Hospital, School of Medicine, Tilki, Derya, Willemse, Peter-Paul M.; Davis, Niall F.; Grivas, Nikolaos; Zattoni, Fabio; Lardas, Michael; Briers, Erik; Cumberbatch, Marcus G.; De Santis, Maria; Dell'Oglio, Paolo; Donaldson, James F.; Fossati, Nicola; Gandaglia, Giorgio; Gillessen, Silke; Grummet, Jeremy P.; Henry, Ann M.; Liew, Matthew; MacLennan, Steven; Mason, Malcolm D.; Moris, Lisa; Plass, Karin; O'Hanlon, Shane; Omar, Muhammad Imran; Oprea-Lager, Daniela E.; Pang, Karl H.; Paterson, Catherine C.; Ploussard, Guillaume; Rouvière, Olivier; Schoots, Ivo G.; van den Bergh, Roderick C.N.; Van den Broeck, Thomas; van der Kwast, Theodorus H.; van der Poel, Henk G.; Wiegel, Thomas; Yuan, Cathy Yuhong; Cornford, Philip; Mottet, Nicolas; Lam, Thomas B.L., Koç University Hospital, and School of Medicine
Context: there is uncertainty regarding the most appropriate criteria for recruitment, monitoring, and reclassification in active surveillance (AS) protocols for localised prostate cancer (PCa). Objective: to perform a qualitative systematic review (SR) to issue recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and repeat biopsy strategy. Evidence acquisition: a protocol-driven, Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-adhering SR incorporating AS protocols published from January 1990 to October 2020 was performed. The main outcomes were criteria for inclusion of intermediate-risk disease, monitoring, reclassification, and repeat biopsy strategies (per protocol and/or triggered). Clinical effectiveness data were not assessed. Evidence synthesis: of the 17 011 articles identified, 333 studies incorporating 375 AS protocols, recruiting 264 852 patients, were included. Only a minority of protocols included the use of magnetic resonance imaging (MRI) for recruitment (n = 17), follow-up (n = 47), and reclassification (n = 26). More than 50% of protocols included patients with intermediate or high-risk disease, whilst 44.1% of protocols excluded low-risk patients with more than three positive cores, and 39% of protocols excluded patients with core involvement (CI) >50% per core. Of the protocols, ?80% mandated a confirmatory transrectal ultrasound biopsy; 72% (n = 189) of protocols mandated per-protocol repeat biopsies, with 20% performing this annually and 25% every 2 yr. Only 27 protocols (10.3%) mandated triggered biopsies, with 74% of these protocols defining progression or changes on MRI as triggers for repeat biopsy. Conclusions: for AS protocols in which the use of MRI is not mandatory or absent, we recommend the following: (1) AS can be considered in patients with low-volume International Society of Urological Pathology (ISUP) grade 2 (three or fewer positive cor, NA